Trius Therapeutics initiates phase 3 clinical trial of oral torezolid phosphate for treatment of ABS

Trius Therapeutics, Inc. has conducted its Phase 3 clinical study of the oral dosage form of torezolid phosphate (DA-7218) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), Dong-A Pharm said on August 30.

The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezol...